Poster Listings Session 53 <strong>CROI</strong> 2013 c Monday, 2:30-4 pm; Hall B2 Session 53–Poster Abstracts HIV Persistence, Reservoirs, and Viremic Control 170aLB Impact of Interleukin-7 and Raltegravir + Maraviroc Intensification on Total HIV DNA Reservoir: Results from ERAMUNE 01 Christine Katlama* 1 , S Lambert 2 , L Assoumou 3 , L Papagno 4 , F Lecardonnel 4 , G Tambussi 5 , B Clotet 6 , M Youle 7 , D Costagliola 3 , B Autran 8 , and ERAMUNE-01 Study Group 1 Hosp Pitie-Salpetriere, Paris, France;; 2 Lab of Virology, Univ Pierre et Marie Curie Paris 6, INSERM U943, France;; 3 Univ Pierre et Marie Curie Paris 6, INSERM U943, France;; 4 ORVACS with the support of the Bettencourt-Schueller Fndn;; 5 San Raffaele Hosp, Milan, Italy;; 6 Hosp Univ Germans Trias i Pujol, Fndn irsiCaixa, Badalona, Spain;; 7 Royal Free Hosp NHS Trust, London, UK;; and 8 Lab of Cellular and Tissular Immunology, Univ Pierre et Marie Curie Paris 6, INSERM U945, France 175LB Natural Killer Cells Can Target and Eliminate Latently HIV-1 + Primary T Cells following Proviral Reactivation Mary Ann Checkley Luttge*, C Dobrowolski, M Shukla, B Luttge, H Mao, and J Karn Sch of Med, Case Western Reserve Univ, Cleveland, OH, US + 176LB T Cells Is Associated with Lack of Progression in Viremic Individuals Nichole Klatt* 1,2 , S Bosinger3 , A Specht4 , M Lederman5 , D Camerini6 , M Paiardini3 , J Brenchley2 , F Kirchhoff4 , P Hunt7 , and G Silvestri3 1 2 Washington Natl Primate Res Ctr, Univ of Washington, Seattle, US;; Lab of Molecular Microbiology, NIAID, NIH, Bethesda, MD, US;; 3Yerkes Primate Res Ctr, Emory Vaccine Ctr, Emory University, Atlanta, GA, US;; 4 5 Inst of Molecular Virology, Ulm Univ Med Ctr, Germany;; Case Western Reserve Univ/Univ Hosp Case Med Ctr, Cleveland, OH, US;; 6Inst for Immunology, Univ of California, Irvine, US;; and 7UCSF Positive Hlth Prgm, San Francisco, CA, US 177LB Response in HIV-1 Superinfection Antoine Chaillon* 1,2 , G Wagner 1 , J Wertheim 1 , L Hepler 1 , S Kosakovsky Pond 1 , G Caballero 1 , M Pacold 3 , T Wrin 4 , D Richman 1,5 , and D Smith 1,5 1 Univ of California, San Diego, La Jolla, US;; 2 INSERM UMR U966, Tours, France;; 3 Life Technologies, Foster City, CA, US;; 4 Monogram BioSci, Inc, San Francisco, CA, US;; and 5 VA San Diego Hlthcare System, CA, US 24 20th Conference on Retroviruses and Opportunistic Infections c Wednesday, 2:30-4 pm; Hall B2 Session 54–Poster Abstracts ART, Complications, and TB 178LB Results Scott Letendre* 1 , A Mills 2 , K Tashima 3 , D Thomas 4 , S Min 4 , S Chen 4 , I Song 4 , S Piscitelli 4 , and extended ING116070 Study Team 1 UCSD Antiviral Res Ctr, San Diego, CA, US;; 2 Anthony Mills MD, Inc, Los Angeles, CA, US;; 3 The Miriam Hosp, Providence, RI, US;; and 4 GlaxoSmithKline, Research Triangle Park, NC, US 170bLB Early Viral Dynamics after Cord Blood Stem Cell + Patients M Nijhuis1 , M Kwon2 , J Kuball1 , P Ellerbroek1 , J Berenguer2 , A Stam1 , J Symons1 , D Richman3 , JL Diez-Martin2 , Annemarie Wensing* 1 , and European HIV Cure and Transplant Consortium 1 2 Univ Med Ctr Utrecht, The Netherlands;; Gregorio Maranon G U Hosp, Madrid, Spain;; and 3Univ of California, San Diego, US 171LB competent HIV Reservoirs in Perinatally Infected Youth Treated from Infancy: Towards Cure Katherine Luzuriaga* 1 , YH Chen2 , C Ziemniak2 , G Siberry3 , M Strain4 , D Richman4 , T-W Chun5 , C Cunningham6 , and D Persaud2 1 2 Univ of Massachusetts Med Sch, Worcester, US;; Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 3Maternal and Pediatric Infectious Disease Branch, NICHD, NIH, Bethesda, MD, US;; 4Univ of California San Diego, La Jolla and VA San Diego Hlthcare System, US;; 5NIAID, NIH, Bethesda, MD, US;; and 6Duke Univ Sch of Med, Durham, NC, US 172LB HIV-1 DNA Decay Patterns in Blood during More than a Guillaume Besson* 1 , C Lalama2 , R Bosch2 , R Gandhi3 , M Bedison1 , E Aga2 , S Riddler1 , D McMahon1 , F Hong1 , and J Mellors1 1Univ of Pittsburgh Sch of Med, Division of Infectious Diseases, PA, US;; 2Ctr for Biostatistics in AIDS Res, Harvard Sch of Publ Hlth, Boston, MA, US;; and 3Massachusetts Gen Hosp and Ragon Inst, Harvard Med Sch, Boston, US 173LB Multifocal Detection of HIV-1 RNA in Lymphatic Tissues during Early Viral Recrudescence after Treatment Interruption Meghan Rothenberger* 1 , M Stevenson2 , G Beilman1 , J Chipman1 , A Khoruts1 , C Fletcher3 , C Reilly1 , S Wietgrefe1 , A Haase1 , and T Schacker1 1 2 3 Univ of Minesota, Minneapolis, US;; Univ of Miami, FL, US;; and Univ of Nebraska, Omaha, US 174LB A Rapid Virion Recovery Assay Reveals a Larger Population + T Cells than Previously Recognized Michele Sobolewski* 1 , A Cillo1 , C Lalama2 , R Bosch2 , and J Mellors1 179LB Anton Pozniak* 1 2 Univ of Pittsburgh, PA, US and Harvard Univ, Boston, MA, US 1 , H Mingrone2 , A Shuldyakov3 , C Brites4 , J Andrade5 , D Hagins6 , C Beltran Buendia7 , D Dorey8 , S Griffith9 , and S Min9 1 2 Chelsea and Westminster Hosp, London, UK;; Ciudad Autonoma de Buenos Aires, Argentina;; 3Saratov Regional Ctr of Prophylactic AIDS, Russian Federation;; 4Hosp Univ Professor Edgar Santos, Salvador, Brazil;; 5Hosp Civil de Guadalajare Fray Antonio Alcalde, Mexico;; 6 7 Chatham CARE Ctr, Savannah, GA, US;; Hosp Barros Luco Trudeau, Santiago, Chile;; 8GlaxoSmithKline, Mississauga, Canada;; and 9GlaxoSmithKline, Research Triangle Park, NC, US 180LB RTI or Raltegravir in HIV + st - Mark Boyd and SECOND-LINE Study Team The Kirby Inst, Univ of New South Wales, Sydney, Australia 181LB Increasing Retention of Patients Starting ART: Karonga Rein Houben* 1 , T Mzembe2 , T van Boeckel3 , L Munthali2 , P Mzumara4 , A Jahn5 , F Chimbwandira5 , J Glynn1 , and A Crampin1,2 1 2 London Sch of Hygiene and Tropical Med, UK;; Karonga Prevention Study, Chilumba, Malawi;; 3Univ Libre de Bruxelles, Belgium;; 4Karonga District Hosp, Malawi;; and 5Ministry of Hlth, Lilongwe, Malawi 182LB Efficacy and Safety of Maraviroc to Prevent Immune Reconstitution Inflammatory Syndrome in High-risk Juan Sierra-Madero* 1 , A Tierney2 , M Rassool3 , L Azzoni4 , I Sereti5 , J Andrade6 , L Mosqueda-Gomez7 , A Pineirua1 , I Sanne3 , M Lederman8 , and CADIRIS Study Team 1Inst Nacional de Ciencias Med y Nutricion SZ, Mexico City, Mexico;; 2 3 Univ of Pennsylvania, Philadelphia, US;; Clin HIV Res Unit Faculty of Hlth Sci, Univ of the Witwatersrand;; 4The Wistar Inst, Philadelphia, PA, US;; 5NIAID, NIH, Bethesda, MD, US;; 6Hosp Civil de Guadalajara, Mexico;; 7Capasits, Leon, Mexico;; and 8Case Western Reserve Univ, Cleveland, OH, US 183LB No Difference in Risk of Preterm Birth among Pregnant Ugandan Women Randomized to Lopinavir/Ritonavir vs Deborah Cohan* 1 , P Natureeba2 , A Plenty1 , F Luwedde2 , J Mwesigwa2 , V Ades3 , B Nzarubara2 , T Clark1 , B Osterbauer1 , and E Charlebois1 1 2 Univ of California, San Francisco, US;; Infectious Disease Res Collaboration, Kampala, Uganda;; and 3New York Univ, NY, US st 184LB -Line ART Do Not Persist + African Children: The 5-Year ARROW Trial Patricia Nahirya-Ntege* 1 , A Cook2 , V Musiime3 , A Kekitiinwa4 , K Nathoo5 , P Munderi1 , P Mugyenyi3 , S Bakeera-Kitaka4 , S Walker2 , and D Gibb2 1 2 MRC/UVRI Uganda Res Unit on AIDS, Entebbe;; MRC Clinical Trials Unit, London, UK;; 3Joint Clinical Res Ctr, Kampala, Uganda;; 4Baylor- Uganda/Paediatric Infectious Diseases Clin, Mulago, Kampala;; and 5Univ of Zimbabwe, Harare 185LB Non-Calcified Coronary Plaque and Macrophage Activation Markers Are Increased in HIV + Women Kathleen Fitch* 1 , S Abbara 1 , T Burdo 2 , K Williams 2 , P Eneh 1 , J Lo 1 , and S Grinspoon 1 1 Massachusetts Gen Hosp, Boston, US and 2 Boston Coll, Chestnut Hill, MA, US 186LB Effect of Statins on Immune Activation and Inflammation in HIV + Trial Grace McComsey* 1,2,3 , Y Jiang 1 , S Debanne 1 , B Clagett 1 , J Robinson 1 , D Labbato 1,2,3 , N Storer 1,2,3 , M Lederman 1,2 , and N Funderburg 1 1 Case Western Reserve Univ, Cleveland, OH, US;; 2 Univ Hosp Case Med Ctr, Cleveland, OH, US;; and 3 Cleveland, OH, US 187LB Craig Sponseller* 1 , R Morgan 2 , S Campbell 2 , J Aberg 3 , and M Thompson 4 1 Kowa Pharmaceuticals America, Inc, Montgomery, AL;; 2 Kowa Res Inst, Inc, Morrisville, NC, US;; 3 New York Univ Sch of Med, NY, US;; and 4 AIDS Res Consortium of Atlanta, GA, US
<strong>CROI</strong> 2013 Session 57 188LB Kelly Dooley* 1 , A Luetkemeyer2 , J-G Park3 , R Allen4 , D Sutherland5 , F Aweeka2 , S Koletar6 , Y Cramer3 , J Bao7 , D Haas5 , and A5306 Study Team 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; Univ of California, San Francisco, US;; 3Statistical and Data Analysis Ctr, Harvard Sch of Pub Hlth, Cambridge, MA, US;; 4Social and Sci Systems, Inc, Silver Spring, MD, US;; 5Vanderbilt Univ Sch of Med, Nashville, TN, US;; 6Ohio State Univ, Columbus, US;; and 7Division of AIDS, NIH, Bethesda, MD, US 189LB the Benefit of Concurrent Isoniazid Preventive Therapy with ART of a Randomized Controlled Trial Molebogeng Rangaka* 1,2,3 , R Wilkinson2,4,5,6 , K Wilkinson2,5 , J Glynn3 , A Boulle1 , G Maartens7 , and ART plus IPT Study Team 1Ctr for Infectious Disease Epidemiology and Res, Sch of Hlth Sci, Cape Town, South Africa;; 2Clinical Infectious Disease Res Initiative, Univ of Cape Town, South Africa;; 3London Sch of Hygiene and Tropical Med, UK;; 4Inst of Infectious Diseases and Molecular Med;; 5MRC Natl Inst for Med Res, London, UK;; 6 201 Divergent Patterns of CCR5 versus Alternative Co-receptormediated Entry in Pathogenic Rhesus Macaque and Non- Sarah Elliott* Imperial Coll London, Norfolk Place, UK;; and 7Univ of Cape Town, South Africa 1 , N Riddick1 , N Francella1 , M Paiardini2 , C Derdeyn2 , G Silvestri2 , and R Collman1 1 2 Univ of Pennsylvania, Philadelphia, US and Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US 202 HIV-1 Tropism and Co-receptor Binding Stoichiometry Melissa Zarr* 1 and R Siliciano1,2 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US and Howard Hughes Med Inst, Baltimore, MD, US 203 Are Highly Permissive to HIV-1 ex vivo S Kohler, Joy Folkvord*, and E Connick Univ of Colorado Denver, Aurora, US 204 Monitoring HIV-1 Envelope Maturation Z Stolp, S Diaz, A Stotland, B Hilton, and Roland Wolkowicz* San Diego State Univ, CA, US 205 + T Lymphocytes + 190LB Patients in a Medium Burden TB Setting Jonathan Golub* 1,2 , V Saraceni3 , S Cavalcante3,4 , S Cohn1 , A Pacheco4 , L Moulton1,2 , R Chaisson1,2 , and B Durovni3,5 1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 3 Rio de Janeiro City Hlth Secretariat, Brazil;; 4 FIOCRUZ, Rio de Janeiro, Brazil;; and 5 Federal Univ of Rio de Janeiro, Brazil c Monday, 2:30-4 pm; Hall B2 Session 55–Poster Abstracts Envelope/Entry/Tropism/Transmission 192 Dendritic Cell-to-T Cell HIV Transmission Is a Drug-insensitive Mode of Infection Jocelyn Kim* 1,2 , A Sigal 1 , and D Baltimore 1 Eveline Santos da Silva* 1 , M Mulinge 1 , M Lemaire 1 , A Rybicki 1 , C Masquelier 1 , J-Y Servais 1 , J-C Schmit 1,2 , and D Perez Bercoff 1 1 CRP-Sante, Luxembourg and 2 Ctr Hosp de Luxembourg c Tuesday, 2:30-4 pm; Hall B2 Session 56–Poster Abstracts Transcription/Reverse and Forward, Splicing/Replication 206 Cyclin-dependent Kinases Support HIV-1 Reverse Transcription Jin Leng* 1,2 , H-P Ho 3 , M Buzon 1,2 , F Pereyra 2,4 , X Yu 2 , E Chang 3 , and M Lichterfeld 1 1 Massachusetts Gen Hosp, Boston, US;; 2 Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US;; 3 City Univ of New York, NY, US;; and 4 1 2 California Inst of Tech, Pasadena, US and David Geffen Sch of Med, Univ of California, Los Angeles, US 193 Actin Dynamics Differentially Regulate Cell-to-Cell Transfer + T Cells Marc Permanyer*, E Pauls, B Clotet, and J Este IrsiCaixa AIDS Res Inst, Badalona, Spain 194 Virological Synapse Target Cells Talia Swartz*, A Esposito, N Durham, and B Chen Mt Sinai Sch of Med, New York, NY, US 195 Maria Blasi* 1 , P Chen2 , B Chen2 , B Balakumaran1 , D Negri1,3 , A Cara1,3 , and M Klotman1 1 2 Duke Univ Med Ctr, Durham, NC, US;; Mt Sinai Sch of Med, New York, NY, US;; and 3Inst Superiore di Sanita, Rome, Italy 196 MS Valera1 , S Ziglio1 , Laura de Armas Rillo* 1 , J Barroso Gonzalez1 , L Garcia Exposito1 , I Puigdomenech2 , JD Machado1 , J Blanco2 , and A Valenzuela-Fernandez1 1 2 Univ of La Laguna, Spain and Univ Autonoma de Barcelona, Spain + 197 Adhesion Molecule Mediated Virus Adsorption Joseph Kononchik Jr* and P Sun NIAID, NIH, Rockville, MD, US 198 P Colin1 , Y Benureau1 , I Staropoli1 , Y Wang1 , O Hartley2 , A Brelot1 , F Arenzana-Seisdedos1 , and Bernard Lagane* 1 1 2 Inst Pasteur, Paris, France and Univ of Geneva, Switzerland 199 Kelechi Chikere* 1 , N Webb1 , T Chou1 , P Gorry2 , and B Lee1 1 2 Univ of California, Los Angeles, US and Burnet Inst, Melbourne, Australia 200 HIV-1 Co-receptor Switch in Treatment-naïve Patients: Virginie Mortier* 1 , D Staelens1 , K Dauwe1 , L Vancoillie1 , W Cabooter2 , F Van Wanzeele3 , L Vandekerckhove3 , D Vogelaers3 , K Chalmet1 , and C Verhofstede1 207 HIV-1 Vpu and Cellular TASK Proteins Suppress Transcription of Unintegrated HIV-1 DNA Nkiruka Emeagwali* 1 2 3 Ghent Univ, Belgium;; MSD Belgium;; and Ghent Univ Hosp, Belgium 1 and J Hildreth2 1 2 Warren Alpert Med Sch of Brown Univ, Providence, RI, US and Univ of California, Davis, US 208 Alona Kuzmina* 1 , N Verstraete2 , O Bensaude2 , and R Taube1 1 2 Ben Gurion Univ of the Negev, Beer Sheba, Israel and Inst de Biologie de l’Ecole Normale Superieure, Paris, France 209 Identification of Anti-HIV Activity of RNA Processing/Splicing Yoon-Jeoung Koh* and J-C You Natl Res Lab for Molecular Virology, Catholic Univ of Korea Sch of Med, Seoul 210 Staufen-1 Interacts with HIV-1 Rev and HERV-K Rec Proteins to Assist in Nucleocytoplasmic Viral RNA Transport K Hanke, O Hohn, K Fiddeke, and Norbert Bannert* Robert Koch Inst, Berlin, Germany 211 in HIV Transcription Alba Ruiz*, E Pauls, B Clotet, and J EsteRetrovirology Lab Irsi Caixa, Hosp Germans Trias i Pujol, Badalona, Spain 212 HIV-1 Replication in Jurkat T Cells Ananda Ayyappan Jaguva Vasudevan* 1 , M Kramer1 , A Hain1 , R Linka2 , R Hartig2 , B Schraven1 , D Haussinger1 , A Borkhardt1 , and C Munk1 1Heinrich Heine Univ, Med Faculty, Dusseldorf, Germany and 2Otto-von-Guericke Univ of Magdeburg, Germany c Wednesday, 2:30-4 pm; Hall B2 Session 57–Poster Abstracts Accessory Proteins/Gag 213 Sreya Tarafdar* 1,2 , J Poe1 , and T Smithgall1 1 2 Univ of Pittsburgh Sch of Med, PA, US and Univ of Pittsburgh Grad Sch of Publ Hlth, PA, US 214 Vpr Is Required for the Expression and Replication of + T Cells Benjamin Trinite*, E Ohlson, S Rana, J Alster, I Voznesensky, and D Levy New York Univ Coll of Dentistry, NY, US <strong>Program</strong> 25 Poster Listings
- Page 1 and 2: Pocket Program CR I 2O13 20th Confe
- Page 3 and 4: vi General Information CROI 2013 AB
- Page 5 and 6: viii General Information CROI 2013
- Page 7 and 8: x Hotel Information CROI 2013 Map K
- Page 9 and 10: CROI 2013 Session 2 j Sunday, 9 am-
- Page 11 and 12: CROI 2013 Session 8 i Monday, 8:30-
- Page 13 and 14: CROI 2013 Session 12 k Monday, 10 a
- Page 15 and 16: CROI 2013 Session 16 b Monday, 1:30
- Page 17 and 18: CROI 2013 Session 20 e Monday, 4-6
- Page 19 and 20: CROI 2013 Session 26 11:00 85 Impac
- Page 21 and 22: CROI 2013 Session 31 1023 Risk Fact
- Page 23 and 24: CROI 2013 Session 34 e Tuesday, 4-6
- Page 25 and 26: CROI 2013 Session 40 i Wednesday, 8
- Page 27 and 28: CROI 2013 Session 45 11:00 153LB Om
- Page 29 and 30: CROI 2013 Session 49 1103 Attrition
- Page 31: CROI 2013 Session 52 e Wednesday, 4
- Page 35 and 36: CROI 2013 Session 65 c Tuesday, 2:3
- Page 37 and 38: CROI 2013 Session 70 c Wednesday, 2
- Page 39 and 40: CROI 2013 Session 75 329 Impact of
- Page 41 and 42: CROI 2013 Session 82 369 Transcrip
- Page 43 and 44: CROI 2013 Session 89 413 Risk of Cl
- Page 45 and 46: CROI 2013 Session 93 456 A Longitud
- Page 47 and 48: CROI 2013 Session 100 c Tuesday, 2:
- Page 49 and 50: CROI 2013 Session 106 c Monday, 2:3
- Page 51 and 52: CROI 2013 Session 111 c Wednesday,
- Page 53 and 54: CROI 2013 Session 117 616 Immigran
- Page 55 and 56: CROI 2013 Session 122 656 Compariso
- Page 57 and 58: CROI 2013 Session 125 c Tuesday, 2:
- Page 59 and 60: CROI 2013 Session 131 c Monday, 2:3
- Page 61 and 62: CROI 2013 Session 137 c Tuesday, 2:
- Page 63 and 64: CROI 2013 Session 144 809 Prevalenc
- Page 65 and 66: CROI 2013 Session 150 847 Improving
- Page 67 and 68: CROI 2013 Session 161 885 The Impac
- Page 69 and 70: CROI 2013 Session 171 + 924 Women
- Page 71 and 72: CROI 2013 Session 180 c Wednesday,
- Page 73 and 74: CROI 2013 Session 187 994 Protecti
- Page 75 and 76: CROI 2013 Session 192 1032b Changes
- Page 77 and 78: CROI 2013 Session 197 1074 Alexa
- Page 79 and 80: CROI 2013 Session 199 nd 1113 -lin
- Page 81 and 82: POSTER SESSIONS Poster Hall open fr